Altimmune (ALT)
(Delayed Data from NSDQ)
$6.58 USD
-0.17 (-2.52%)
Updated Jul 29, 2024 04:00 PM ET
After-Market: $6.57 -0.01 (-0.15%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ALT 6.58 -0.17(-2.52%)
Will ALT be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ALT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ALT
Brookdale Senior (BKD) Q2 Occupancy Jumps, Growth Trend Persists
The Zacks Analyst Blog Highlights Stocks recently featured in the blog include: Novo Nordisk, Eli Lilly's, Viking, Altimmune, Roche and Amgen
ALT: What are Zacks experts saying now?
Zacks Private Portfolio Services
4 Stocks That Could Break Novo Nordisk, Lilly's Obesity Duopoly
Altimmune (ALT) Moves to Buy: Rationale Behind the Upgrade
Altimmune (ALT) to Report Q4 Earnings: What's in the Cards?
Other News for ALT
Altitude Group Reports Record Financial Growth
Altitude Group Schedules Interactive Investor Presentation
Altimmune Announces Publication of Clinical Study of Pemvidutide in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Journal of Hepatology
Altimmune announces publication of study of pemvidutide in MASLD
Viking sends Lilly, Novo lower as obesity drug enters late-stage program